Cite
Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein Eε4.
MLA
Pollen, Daniel A1, et al. “Prevention of Alzheimer’s Disease in High Risk Groups: Statin Therapy in Subjects with PSEN1 Mutations or Heterozygosity for Apolipoprotein Eε4.” Alzheimer’s Research & Therapy, vol. 2, no. 5, Sept. 2010, pp. 1–7. EBSCOhost, https://doi.org/10.1186/alzrt55.
APA
Pollen, D. A., Baker, S., Hinerfeld, D., Swearer, J., Evans, B. A., Evans, J. E., Caselli, R., Rogaeva, E., St George-Hyslop, P., & Moonis, M. (2010). Prevention of Alzheimer’s disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein Eε4. Alzheimer’s Research & Therapy, 2(5), 1–7. https://doi.org/10.1186/alzrt55
Chicago
Pollen, Daniel A1, Stephen Baker, Douglas Hinerfeld, Joan Swearer, Barbara A. Evans, James E. Evans, Richard Caselli, Ekaterina Rogaeva, Peter St George-Hyslop, and Majaz Moonis. 2010. “Prevention of Alzheimer’s Disease in High Risk Groups: Statin Therapy in Subjects with PSEN1 Mutations or Heterozygosity for Apolipoprotein Eε4.” Alzheimer’s Research & Therapy 2 (5): 1–7. doi:10.1186/alzrt55.